PMID- 33936073
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220422
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - COVID-19 Among Patients With Inflammatory Rheumatic Diseases.
PG  - 651715
LID - 10.3389/fimmu.2021.651715 [doi]
LID - 651715
AB  - BACKGROUND: The course of novel coronavirus disease 2019 (COVID-19) has been of 
      special concern in patients with inflammatory rheumatic diseases (IRDs) due to 
      the immune dysregulation that may be associated with these diseases and the 
      medications used for IRDs, that may affect innate immune responses. OBJECTIVE: In 
      this cohort study, we aimed to report the disease characteristics and variables 
      associated with COVID-19 outcome among Turkish patients with IRDs. METHODS: 
      Between April and June, 2020, 167 adult IRD patients with COVID-19 were 
      registered from 31 centers in 14 cities in Turkey. Disease outcome was classified 
      in 4 categories; (i) outpatient management, (ii) hospitalization without oxygen 
      requirement, (iii) hospitalization with oxygen requirement, and (iv) intensive 
      care unit (ICU) admission or death. Multivariable ordinal logistic regression 
      analysis was conducted to determine variables associated with a worse outcome. 
      RESULTS: 165 patients (mean age: 50 +/- 15.6 years, 58.2% female) were included. 
      Twenty-four patients (14.5%) recovered under outpatient management, 141 (85.5%) 
      were hospitalized, 49 (30%) required inpatient oxygen support, 22 (13%) were 
      treated in the ICU (17 received invasive mechanic ventilation) and 16 (10%) died. 
      Glucocorticoid use (OR: 4.53, 95%CI 1.65-12.76), chronic kidney disease (OR: 
      12.8, 95%CI 2.25-103.5), pulmonary disease (OR: 2.66, 95%CI 1.08-6.61) and 
      obesity (OR: 3.7, 95%CI 1.01-13.87) were associated with a worse outcome. 
      Biologic disease-modifying antirheumatic drugs (DMARDs) do not seem to affect 
      COVID-19 outcome while conventional synthetic DMARDs may have a protective effect 
      (OR: 0.36, 95%CI 0.17-0.75). Estimates for the associations between IRD diagnoses 
      and outcome were inconclusive. CONCLUSIONS: Among IRD patients with COVID-19, 
      comorbidities and glucocorticoid use were associated with a worse outcome, while 
      biologic DMARDs do not seem to be associated with a worse outcome.
CI  - Copyright (c) 2021 Esatoglu, Tascilar, Babaoglu, Bes, Yurttas, Akar, Pehlivan, 
      Akleylek, Tecer, Seyahi, Yuce-Inel, Alpay-Kanitez, Bodakci, Tekgoz, Colak, Bolek, 
      Koca, Kalyoncu, Icacan, Ugurlu, Oz, Hamuryudan, Hatemi and the Turkish Society 
      for Rheumatology COVID-19 Registry Investigators.
FAU - Esatoglu, Sinem Nihal
AU  - Esatoglu SN
AD  - Department of Rheumatology, Gaziosmanpasa Research and Training Hospital, Health 
      Sciences University, Istanbul, Turkey.
FAU - Tascilar, Koray
AU  - Tascilar K
AD  - Department of Internal Medicine 3 - Rheumatology and Immunology, 
      Friedrich-Alexander University Erlangen- Nuremberg and Universitatsklinikum 
      Erlangen, Erlangen, Germany.
FAU - Babaoglu, Hakan
AU  - Babaoglu H
AD  - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, 
      Gazi University, Ankara, Turkey.
FAU - Bes, Cemal
AU  - Bes C
AD  - Department of Rheumatology, Sadi Konuk Education and Research Hospital, Health 
      Sciences University, Istanbul, Turkey.
FAU - Yurttas, Berna
AU  - Yurttas B
AD  - Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Faculty of 
      Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
FAU - Akar, Servet
AU  - Akar S
AD  - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, 
      Izmir Katip Celebi University, Izmir, Turkey.
FAU - Pehlivan, Ozlem
AU  - Pehlivan O
AD  - Department of Rheumatology, Umraniye Training and Research Hospital, Istanbul, 
      Turkey.
FAU - Akleylek, Cansu
AU  - Akleylek C
AD  - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, 
      TC Demiroglu Bilim University, Istanbul, Turkey.
FAU - Tecer, Duygu
AU  - Tecer D
AD  - Department of Rheumatology, Gulhane Faculty of Medicine, Health Sciences 
      University, Ankara, Turkey.
FAU - Seyahi, Emire
AU  - Seyahi E
AD  - Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Faculty of 
      Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
FAU - Yuce-Inel, Tuba
AU  - Yuce-Inel T
AD  - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, 
      Dokuz Eylul University, Izmir, Turkey.
FAU - Alpay-Kanitez, Nilufer
AU  - Alpay-Kanitez N
AD  - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, 
      Koc University, Istanbul, Turkey.
FAU - Bodakci, Erdal
AU  - Bodakci E
AD  - Department of Rheumatology, Eskisehir City Hospital, Eskisehir, Turkey.
FAU - Tekgoz, Emre
AU  - Tekgoz E
AD  - Department of Rheumatology, Gulhane Faculty of Medicine, Health Sciences 
      University, Ankara, Turkey.
FAU - Colak, Seda
AU  - Colak S
AD  - Department of Rheumatology, Gulhane Faculty of Medicine, Health Sciences 
      University, Ankara, Turkey.
FAU - Bolek, Ertugrul Cagri
AU  - Bolek EC
AD  - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, 
      Hacettepe University, Ankara, Turkey.
FAU - Koca, Suleyman Serdar
AU  - Koca SS
AD  - Division of Rheumatology, Department of Internal Medicine, School of Medicine, 
      Firat University, Elazig, Turkey.
FAU - Kalyoncu, Umut
AU  - Kalyoncu U
AD  - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, 
      Hacettepe University, Ankara, Turkey.
FAU - Icacan, Ozan Cemal
AU  - Icacan OC
AD  - Department of Rheumatology, Sadi Konuk Education and Research Hospital, Health 
      Sciences University, Istanbul, Turkey.
FAU - Ugurlu, Serdal
AU  - Ugurlu S
AD  - Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Faculty of 
      Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
FAU - Oz, Hande Ece
AU  - Oz HE
AD  - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, 
      Izmir Katip Celebi University, Izmir, Turkey.
FAU - Hamuryudan, Vedat
AU  - Hamuryudan V
AD  - Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Faculty of 
      Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
FAU - Hatemi, Gulen
AU  - Hatemi G
AD  - Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Faculty of 
      Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
CN  - Turkish Society for Rheumatology COVID-19 Registry Investigators
LA  - eng
PT  - Journal Article
DEP - 20210416
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Glucocorticoids)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Ambulatory Care
MH  - Antirheumatic Agents/adverse effects/*therapeutic use
MH  - COVID-19/*complications/immunology/mortality/physiopathology
MH  - Cohort Studies
MH  - Comorbidity
MH  - Critical Care
MH  - Female
MH  - Glucocorticoids/*adverse effects/therapeutic use
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Oxygen Inhalation Therapy
MH  - Regression Analysis
MH  - Rheumatic Diseases/complications/*immunology/mortality/physiopathology
MH  - Turkey
PMC - PMC8086428
OTO - NOTNLM
OT  - COVID-19
OT  - DMARDs
OT  - SARS CoV-2
OT  - biologic DMARDs
OT  - rheumathoid diseases
COIS- KT has served as a speaker for Gilead. GH has received grant/research support 
      from Celgene and has served as a speaker for AbbVie, Celgene, Novartis, and UCB 
      Pharma. The remaining authors declare that the research was conducted in the 
      absence of any commercial or financial relationships that could be construed as a 
      potential conflict of interest.
FIR - Cefle, Ayse
IR  - Cefle A
FIR - Karakas, Ali
IR  - Karakas A
FIR - Kaskari, Derya
IR  - Kaskari D
FIR - Karahan, Samet
IR  - Karahan S
FIR - Tezcan, Dilek
IR  - Tezcan D
FIR - Tufan, Abdurrahman
IR  - Tufan A
FIR - Ayan, Ayse
IR  - Ayan A
FIR - Kilic, Levent
IR  - Kilic L
FIR - Donmez, Salim
IR  - Donmez S
FIR - Erdogan, Mustafa
IR  - Erdogan M
FIR - Yazisiz, Veli
IR  - Yazisiz V
FIR - Gok, Edip Gokalp
IR  - Gok EG
FIR - Yucel, Ahmet Eftal
IR  - Yucel AE
FIR - Nas, Elif Dincses
IR  - Nas ED
FIR - Kimyon, Gezmis
IR  - Kimyon G
FIR - Dalgic, Gunay Sahin
IR  - Dalgic GS
FIR - Erdem, Hakan
IR  - Erdem H
FIR - Abacar, Kerem Yigit
IR  - Abacar KY
FIR - Mercan, Ridvan
IR  - Mercan R
FIR - Karadag, Omer
IR  - Karadag O
FIR - Gercik, Onay
IR  - Gercik O
FIR - Ozbek, Suleyman
IR  - Ozbek S
FIR - Gider, Sebnem
IR  - Gider S
FIR - Gulle, Semih
IR  - Gulle S
FIR - Osken, Sibel
IR  - Osken S
FIR - Kiraz, Sedat
IR  - Kiraz S
FIR - Kasifoglu, Timucin
IR  - Kasifoglu T
FIR - Alibaz-Oner, Fatma
IR  - Alibaz-Oner F
FIR - Fresko, Izzet
IR  - Fresko I
FIR - Akdogan, Ali
IR  - Akdogan A
FIR - Yilmaz, Neslihan
IR  - Yilmaz N
EDAT- 2021/05/04 06:00
MHDA- 2021/05/15 06:00
PMCR- 2021/04/16
CRDT- 2021/05/03 06:11
PHST- 2021/01/10 00:00 [received]
PHST- 2021/03/26 00:00 [accepted]
PHST- 2021/05/03 06:11 [entrez]
PHST- 2021/05/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2021/04/16 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.651715 [doi]
PST - epublish
SO  - Front Immunol. 2021 Apr 16;12:651715. doi: 10.3389/fimmu.2021.651715. eCollection 
      2021.